What the FDA labels say about taking them together
Nirmatrelvir/ritonavir and quetiapine
Nirmatrelvir/ritonavir's FDA label of February 19, 2026 names quetiapine in its drug interactions section; the quetiapine labels PlainMeds reads (2) do not name nirmatrelvir/ritonavir. The nirmatrelvir/ritonavir label: “If co-administration is necessary, reduce quetiapine dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations.”
Check it at the source: the nirmatrelvir/ritonavir FDA label on DailyMed (effective February 19, 2026, Pfizer Laboratories Div Pfizer Inc); the quetiapine FDA label on DailyMed (effective April 10, 2026, H2-Pharma, LLC).
What does the nirmatrelvir/ritonavir label say about quetiapine?
Nirmatrelvir/ritonavir label, drug interactionsDrug Class: Antipsychotics; Drugs within Class: quetiapine; Effect on Concentration: ↑ quetiapine; Clinical Comments: If co-administration is necessary, reduce quetiapine dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations.
Source: FDA drug label (Paxlovid), Pfizer Laboratories Div Pfizer Inc, effective February 19, 2026 (SPL set 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a), via openFDA; the full label on DailyMed
What does the quetiapine label say about nirmatrelvir/ritonavir?
Quetiapine's label (effective April 10, 2026) and its 1 other brand-application label do not name nirmatrelvir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (SEROQUEL), NDA020639 (Cheplapharm), as published by H2-Pharma, LLC, effective April 10, 2026 (SPL set 8ae62aaf-f8c5-417f-baac-0098369ca322), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
These are the ingredient's own label sentences, repeated in a combination product's or a biosimilar's label. The ingredient pair sets them out with both labels side by side.
Both medicines on the record
| Nirmatrelvir/ritonavir | Quetiapine | |
|---|---|---|
| Labeled for | COVID-19 | Schizophrenia, Bipolar disorder, Depression |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $49.24 per unit 300-100 mg dose pack | $0.127 per tablet 300 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once